VIII. 4. Immunosuppressants

Immunosuppressants calm the immune system, but they also reshape the gut flora and weaken its defense against pathogens — making mindful eating and infection vigilance essential.

Immunosuppressants and the Gut – Suppressing Immunity, Reshaping the Microbiome

When the immune system is silenced, the microbial world inside you responds [24].

The intersection of immunosuppression and gut microbiota was brought into clinical focus by organ transplantation medicine, where the stakes of post-transplant infection are highest and the intensity of immune suppression is greatest. A study by Guo and colleagues published in Transplantation in 2019 characterized gut microbiota in kidney transplant recipients before and after transplantation, across the immediate post-operative period and through the first year of follow-up. [223] The pattern was consistent and clinically significant. In the weeks immediately after transplantation – when immunosuppressive doses are highest and antibiotic prophylaxis is typically administered concurrently – microbial diversity fell substantially. Enterococcus and Enterobacteriaceae, organisms associated with bacteremia (the presence of bacteria in the bloodstream; a rare but serious complication) (the presence of bacteria in the bloodstream) and opportunistic infection, became relatively enriched. Patients who developed post-transplant infections showed lower pre-transplant microbiota diversity than those who did not, suggesting that baseline microbiota composition at transplantation influences infection susceptibility. [224] The mechanistic picture is layered. Calcineurin inhibitors such as tacrolimus directly affect gut motility and may alter bile acid secretion. Mycophenolate mofetil has direct antiproliferative effects on gut epithelial cells in addition to its immunosuppressive activity. Corticosteroids add their own microbiota-dysregulating effects. The combination of these agents, typically used together in transplant protocols, creates a compound ecological disruption that is more than the sum of its parts. [39] The therapeutic implication is that microbiota support – dietary fiber, consideration of targeted probiotics, minimal co-antibiotic exposure where clinically safe – should be part of transplant aftercare protocols rather than an afterthought. Several transplant centers have begun systematic microbiota monitoring in high-risk post-transplant patients, using microbiota composition as an early indicator of infection risk.

Immunosuppressant medications are used across a broad range of clinical contexts: solid organ and stem cell transplantation, autoimmune diseases (rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis), and increasingly in oncology and dermatology. The major drug classes include calcineurin inhibitors (tacrolimus, cyclosporine), mTOR inhibitors (sirolimus, everolimus), antimetabolites (azathioprine, mycophenolate mofetil), and biologics targeting specific immune pathways (anti-TNF agents, anti-interleukin therapies) [224].

The gut microbiota and the mucosal immune system exist in a tightly co-regulated relationship. Commensal bacteria continuously signal to mucosal immune cells, shaping regulatory T-cell populations, secretory IgA production, and mucosal barrier function. Immunosuppressants disrupt this dialogue by altering the immune side of the equation, which in turn removes selective pressures that normally maintain microbial community stability.

Each immunosuppressant class has a distinct microbiota impact profile. Calcineurin inhibitors such as tacrolimus and cyclosporine directly inhibit bacterial growth and alter membrane transport in some bacterial species, acting as quasi-antibiotics in addition to their immune effects. Tacrolimus in particular is associated with significant reductions in microbial diversity and enrichment of opportunistic pathogens in transplant recipients.

Antimetabolites such as azathioprine and mycophenolate mofetil (MMF) suppress rapidly dividing immune cells but also affect the proliferating epithelial cells of the gut lining. MMF is associated with particularly high rates of gastrointestinal side effects – diarrhoea, nausea, mucosal injury – and produces characteristic shifts in microbiota composition including reductions in Lactobacillus and increases in Pseudomonadota (formerly Proteobacteria).

mTOR inhibitors (sirolimus, everolimus) have a distinct microbiota impact profile compared to calcineurin inhibitors. Some animal model data suggest neutral or context-dependent effects on beneficial bacteria, though clinical data in transplant and autoimmune patients are limited. Their net microbiota effect in clinical immunosuppression contexts depends heavily on concurrent medications and the underlying disease.

Biologic immunosuppressants targeting TNF-α (infliximab, adalimumab) or interleukins are increasingly used in inflammatory bowel disease and autoimmune conditions. Their microbiota effects are complex: in IBD, effective anti-inflammatory treatment restores a microbiota-supportive mucosal environment, which can improve dysbiotic patterns. However, profound immunosuppression with biologics also reduces immune surveillance, creating risks for opportunistic microbial expansion.

Infection risk is the dominant clinical concern in immunosuppressed patients, and the gut microbiota is directly implicated. Reduced microbial diversity, expansion of pathobionts, and impaired mucosal immunity together increase susceptibility to bacterial, fungal, and viral gut infections. Clostridioides difficile (formerly Clostridium difficile) infection is particularly prevalent in heavily immunosuppressed patients and is associated with high morbidity in this population.

FMT in immunosuppressed patients is an active area of clinical research, particularly for recurrent C. difficile in transplant recipients. Safety data are accumulating but the field continues to evolve, and FMT in immunosuppressed individuals requires specialist oversight and careful donor screening.

Protecting the Microbiota During Immunosuppressive Therapy

Microbiota support during immunosuppressive therapy is individualised based on the specific drug regimen, underlying condition, infection risk profile, and degree of immunosuppression. There is no single universal protocol; the principles below are applied case by case.

Dietary fiber intake is maintained as a primary microbiota support strategy throughout immunosuppressive therapy. Fermentable substrates support residual commensal activity, SCFA production, and mucus layer maintenance even under immunosuppressive conditions. Food safety considerations apply: raw or unwashed produce, unpasteurised products, and high-risk fermented foods require careful risk-benefit assessment in severely immunocompromised patients.

Food safety is an active clinical topic in immunosuppressed patients. Standard immunosuppression dietary guidance often includes a low-microbial or neutropenic diet during periods of severe immunosuppression, restricting raw foods, unpasteurised products, and certain fermented foods. As immunosuppression is reduced and immune recovery proceeds, dietary restrictions are progressively relaxed.

Probiotic supplementation in immunosuppressed patients is approached with caution. Live organism supplementation carries a risk of bacteraemia or fungaemia in severely immunocompromised individuals. The decision to use probiotics requires individual risk assessment considering the degree of immunosuppression, underlying condition, and specific probiotic strain. Heat-killed bacterial preparations (postbiotics) avoid live organism risk; however, clinical evidence supporting their use in immunosuppressed patients remains limited, and their use should be discussed with the clinical team before initiation.

Antifungal prophylaxis is standard practice in many heavily immunosuppressed patient groups, particularly stem cell and solid organ transplant recipients. Azole antifungals (fluconazole, posaconazole) used for prophylaxis also affect the bacterial microbiota through secondary effects on fungal-bacterial cross-kingdom interactions.

Antibiotic stewardship is particularly important in immunosuppressed patients. This population has higher baseline antibiotic exposure due to infection risk, and each antibiotic course produces additional microbiota disruption on top of immunosuppressant effects. Minimising unnecessary antibiotic use and using targeted narrow-spectrum agents when treatment is required are standard microbiota-protection principles.

Monitoring for opportunistic infections with gut manifestations is part of routine immunosuppressed patient care. Stool surveillance for C. difficile, atypical pathogens, and fungal colonisation guides early intervention before symptomatic infection establishes.

After immunosuppression reduction or cessation, structured microbiota recovery protocols – increased dietary fiber, fermented foods, and in appropriate cases probiotic supplementation – are implemented alongside clinical monitoring of immune reconstitution.

Microbiota Effects

• Immunosuppressants reduce gut microbial diversity through multiple mechanisms: direct antimicrobial drug effects (calcineurin inhibitors), removal of immune selection pressures that maintain commensals, and mucosal barrier disruption reducing the epithelial habitat for colonisation [39].
• Tacrolimus and cyclosporine have direct bacteriostatic effects on certain commensal species through inhibition of bacterial calcineurin-like phosphatases and membrane transport mechanisms, producing antibiotic-like microbiota changes independent of immune suppression [24].
• Antimetabolites (azathioprine, MMF) damage rapidly proliferating intestinal epithelial cells, disrupting the mucosal surface that commensal bacteria colonise and depend on for metabolic exchange, contributing to mucosal dysbiosis.
• Immunosuppression-associated reductions in secretory IgA and mucosal immune cell populations remove the immunological scaffolding that normally maintains commensal dominance and contains pathobionts, allowing opportunistic expansion.
• C. difficile colonisation and infection are significantly more prevalent in immunosuppressed patients due to reduced colonisation resistance – the ability of the intact commensal community to competitively exclude pathogens.
• Fungal-bacterial interactions in the gut are disrupted under immunosuppression, with Candida species frequently expanding and altering the competitive dynamics of the bacterial community through metabolite production and direct inhibitory effects.
• Anti-TNF biologics in IBD patients produce complex microbiota effects: when effective, they reduce intestinal inflammation and partially restore a pro-commensal mucosal environment; when combined with other immunosuppressants, they may compound dysbiotic risk.

Patient Guidance

• Maintain dietary fiber intake throughout immunosuppressive therapy within food safety guidelines for your level of immunosuppression.
• Follow your clinical team's food safety guidance – restrictions on raw produce and unpasteurised products apply during periods of severe immunosuppression.
• Discuss probiotic use with your clinician before initiating – live organism supplements require individual risk assessment in immunosuppressed patients.
• Minimise unnecessary antibiotic use; request targeted narrow-spectrum agents when treatment is required.
• Monitor for signs of C. difficile infection: watery diarrhoea, fever, abdominal pain – report promptly.
• Monitor for oral and intestinal candidiasis signs during immunosuppressive therapy.
• As immunosuppression is reduced, progressively reintroduce dietary diversity and fermented foods.
• After immunosuppression cessation, implement a structured microbiota recovery protocol with your clinical team.
• Attend all scheduled monitoring appointments – stool and blood surveillance guides early intervention.
• Combine immunosuppressive therapy with consistent sleep, stress management, and appropriate physical activity to support immune and microbiota resilience.

References

[24] Sonnenburg JL, Bäckhed F. Diet–microbiota interactions as moderators of human metabolism. Nature. 2016. Link

Review of mechanisms linking the gut microbiota to obesity and type 2 diabetes drawing on translational animal models and human studies. The microbiota emerges as a mediator of dietary impact on host metabolic status, with growing efforts to establish causal relationships in people and develop therapeutic interventions including personalised nutrition.

[39] Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016. Link

Mechanistic review of short-chain fatty acids (SCFAs) — a major class of bacterial metabolites derived from dietary fibre fermentation — as central mediators between diet, gut microbiota, and host physiology. SCFAs activate G-protein-coupled receptors, inhibit histone deacetylases, and serve as energy substrates, thereby influencing metabolic, immune, and epigenetic processes. The authors synthesize evidence implicating SCFA-mediated signalling in both health maintenance and disease pathogenesis. Provides the conceptual backbone for fibre-based and microbiome-directed therapeutic strategies.

[223] Guo Y, Crnkovic CM, Won KJ et al. Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites by microbial metabolism. Drug Metab Dispos. 2019. Link

This study tested whether common gut bacteria metabolize tacrolimus following an earlier observation correlating faecal Faecalibacterium prausnitzii abundance with oral tacrolimus dose in kidney transplant recipients. F. prausnitzii produced two metabolites (major: M1), absent in hepatic microsome incubations. Structural analysis identified M1 as a C-9 keto-reduction product 15-fold less immunosuppressive than tacrolimus. Screening of 22 gut bacteria found most Clostridiales were extensive tacrolimus metabolizers. The findings identify gut bacterial drug inactivation as a likely mechanism of tacrolimus dose variability.

[224] Lee JR, Muthukumar T, Dadhania D et al. Gut microbiota and tacrolimus dosing in kidney transplantation. PLoS ONE. 2015. Link

This pilot study in 19 adult kidney transplant recipients linked gut microbiota composition during the first transplantation month to tacrolimus dose requirements. Patients requiring >=50% dose escalation (n=5) versus stable-dose patients (n=14) had similar initial doses (4.2+/-1.1 vs 3.8+/-0.8 mg/day) but diverged by month end (9.6+/-2.4 vs 3.3+/-1.5 mg/day, p<0.001). Faecal Faecalibacterium prausnitzii abundance in week 1 was 11.8% in escalators versus 0.8% in stable patients (p=0.002, BH-corrected). The findings identify F. prausnitzii as a candidate predictive marker for tacrolimus dosing.